Eli Lilly · Novo Nordisk: GLP-1 Market Growth and Value Comparison
NVO Novo Nordisk ADR
$39.43 -3.12%
View chart & analysis → - 1Eli Lilly achieved explosive revenue growth by expanding its next-generation metabolic and obesity treatment portfolio.
- 2Eli Lilly recorded $86.5 billion in revenue for the 12 months ended September 30, 2026.
- 3Novo Nordisk maintains a strong global presence by providing diabetes and obesity treatments in more than 50 countries.
So what's the key point?
Eli Lilly reached $86.5 billion in revenue as it increased its variety of obesity treatments. Novo Nordisk is also maintaining its market position by supplying treatments to many countries around the world.
Source The Motley Fool +1 · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.